Surgery for pleural mesothelioma that cannot be fully removed
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a partial surgery called pleurectomy can help people with a specific type of mesothelioma that cannot be fully removed. You must have already completed at least 6 weeks of chemotherapy or immunotherapy without the cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of mesothelioma called epithelioid, confirmed by a biopsy.
- The cancer is only on one side of your chest and cannot be fully removed with standard surgery.
- You have finished at least 6 weeks of chemotherapy or immunotherapy (like pemetrexed with platinum or nivolumab/ipilimumab) without the cancer getting worse.
- You are age 18 or older and in relatively good health (ECOG score 0 or 1).
- Your blood counts, kidney function, and liver function are within acceptable ranges.
- If you have HIV, hepatitis B, or hepatitis C, it must be well-controlled with undetectable viral load.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
This research study collects tissue samples from people having surgery for pleural mesothelioma (a rare lung cancer) or other lung diseases. The samples are used to better understand the disease and improve future treatments.
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.